Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-05 · 44 (5) · 1144-1155
DOI: 10.1161/atvbaha.123.320175 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-05. Verfasst von Benjamin N Wadström und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry and the Copenhagen General Population Study, Copenhagen University Hospital-Herlev and Gentofte, Denmark. Departm…. Hauptthemen laut MEDLINE: Apolipoprotein B-100, Biomarkers, Cholesterol, Cholesterol, LDL. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Elevated apoB-containing lipoproteins (=remnants+LDLs [low-density lipoproteins]) are a major risk factor for atherosclerotic cardiovascular disease, including peripheral artery disease (PAD) and myocardial infarction. We tested the hypothesis that remnants and LDL both explain part of the increased risk of PAD conferred by elevated apoB-containing lipoproteins. For comparison, we also studied the risk of chronic limb-threatening ischemia and myocardial infarction. METHODS: apoB, remnant cholesterol, and LDL cholesterol were measured in 93 461 individuals without statin use at baseline from the Copenhagen General Population Study (2003–2015). During up to 15 years of follow-up, 1207 had PAD, 552 had chronic limb-threatening ischemia, and 2022 had myocardial infarction in the Danish National Patient Registry. Remnant and LDL cholesterol were calculated from a standard lipid profile. Remnant and LDL particle counts were additionally measured with nuclear magnetic resonance spectroscopy in 25 347 of the individuals. Results were replicated in 302 167 individuals without statin use from the UK Biobank (2004–2010). RESULTS: In the Copenhagen General Population Study, multivariable adjusted hazard ratios for risk of PAD per 1 mmol/L (39 mg/dL) increment in remnant and LDL cholesterol were 1.9 (95% CI, 1.5–2.4) and 1.1 (95% CI, 1.0–1.2), respectively; corresponding results in the UK Biobank were 1.7 (95% CI, 1.4–2.1) and 0.9 (95% CI, 0.9–1.0), respectively. In the association from elevated apoB to increased risk of PAD, remnant and LDL cholesterol explained 73% (32%–100%) and 8% (0%–46%), respectively; corresponding results were 63% (30%–100%) and 0% (0%–33%) for risk of chronic limb-threatening ischemia and 41% (27%–55%) and 54% (38%–70%) for risk of myocardial infarction; results for remnant and LDL particle counts corroborated these findings. CONCLUSIONS: PAD risk conferred by elevated apoB-containing lipoproteins was explained mainly by elevated remnants, while myocardial infarction risk was explained by both elevated remnants and LDL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry and the Copenhagen General Population Study, Copenhagen University Hospital-Herlev and Gentofte, Denmark. Department of Clinical Medicine, Faculty of Health and Medical Sciences, Univ…
ORCID-Profile: Benjamin N Wadström, Kasper M Pedersen, Anders B Wulff
Zitieren
APA
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024). Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(5), 1144-1155. https://doi.org/10.1161/atvbaha.123.320175
Vancouver
Wadström BN, Pedersen KM, Wulff AB, Nordestgaard BG. Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(5):1144-1155. doi:10.1161/atvbaha.123.320175
BibTeX
@article{Wadstrm2024,
author = {Wadström, Benjamin N and Pedersen, Kasper M and Wulff, Anders B and Nordestgaard, Børge G},
title = {Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
volume = {44},
number = {5},
pages = {1144--1155},
doi = {10.1161/atvbaha.123.320175}
}
EUVIMED